39.01
前日終値:
$39.05
開ける:
$39.28
24時間の取引高:
2.77M
Relative Volume:
0.93
時価総額:
$4.95B
収益:
$638.78M
当期純損益:
$-22.66M
株価収益率:
-223.68
EPS:
-0.1744
ネットキャッシュフロー:
$122.18M
1週間 パフォーマンス:
+9.18%
1か月 パフォーマンス:
+27.03%
6か月 パフォーマンス:
+134.72%
1年 パフォーマンス:
+199.85%
10 X Genomics Inc Stock (TXG) Company Profile
名前
10 X Genomics Inc
セクター
電話
(925) 401-7300
住所
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY, HNGE
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
TXG
10 X Genomics Inc
|
39.01 | 4.87B | 638.78M | -22.66M | 122.18M | -0.1744 |
|
VEEV
Veeva Systems Inc
|
192.74 | 28.83B | 3.32B | 941.65M | 1.64B | 5.6161 |
|
BTSG
Brightspring Health Services Inc
|
69.03 | 13.69B | 13.65B | 169.86M | 412.12M | 1.0758 |
|
TEM
Tempus Ai Inc
|
60.27 | 10.40B | 1.36B | -302.91M | -219.93M | -1.7182 |
|
HQY
Healthequity Inc
|
95.31 | 7.55B | 1.34B | 230.70M | 440.96M | 2.6695 |
|
HNGE
Hinge Health Inc
|
84.05 | 6.42B | 646.34M | -512.40M | 202.76M | -6.6871 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-12-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | 開始されました | Piper Sandler | Neutral |
| 2025-02-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 開始されました | Leerink Partners | Outperform |
| 2024-07-22 | アップグレード | Jefferies | Hold → Buy |
| 2024-07-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-10 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-06-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-05-01 | ダウングレード | TD Cowen | Buy → Hold |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-05-10 | 開始されました | Barclays | Overweight |
| 2023-03-31 | 開始されました | Stephens | Overweight |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2022-12-14 | 開始されました | Deutsche Bank | Buy |
| 2022-08-18 | ダウングレード | Goldman | Neutral → Sell |
| 2022-07-25 | 開始されました | Canaccord Genuity | Buy |
| 2022-07-15 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-07-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-09-14 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-03-15 | 開始されました | William Blair | Outperform |
| 2020-12-02 | 開始されました | Goldman | Neutral |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-10 | 開始されました | Stifel | Buy |
| 2020-03-05 | 開始されました | Guggenheim | Buy |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-10-07 | 開始されました | BofA/Merrill | Buy |
| 2019-10-07 | 開始されました | Cowen | Outperform |
| 2019-10-07 | 開始されました | JP Morgan | Overweight |
| 2019-09-24 | 開始されました | Evercore ISI | Outperform |
すべてを表示
10 X Genomics Inc (TXG) 最新ニュース
Piper Sandler raises 10X Genomics stock price target on clinical pivot - Investing.com UK
10x Genomics stock hits 52-week high at 37.58 USD - Investing.com
Spatial Genomics and Transcriptomics Market Size to Reach USD 1.90 Billion by 2035, Growing at a 12.23% CAGR | SNS Insider - GlobeNewswire Inc.
10x Genomics, Inc.(NasdaqGS:TXG) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
10x Genomics Inc Class A Actuals & Estimates (FWB:1KJ) - TradingView
1KJ Forecast — Price Target — Prediction for 2027 - TradingView
10x Genomics Inc Class A Actuals & Estimates (DUS:1KJ) - TradingView
Stocks making big moves this week: Qualcomm, Accenture, 10x Genomics, Seagate, and Lattice Semiconductor - Yahoo Finance
Price to earnings forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10x Genomics Inc Class A Actuals & Estimates (MUN:1KJ) - TradingView
Enterprise value to revenue forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x Genomics Inc Class A Actuals & Estimates (NASDAQ:TXG) - TradingView
Enterprise value to EBIT forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10X Genomics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
10x Genomics Inc Class A Actuals & Estimates (LSE:0A88) - TradingView
Enterprise value to EBITDA forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x Genomics Inc Class A Actuals & Estimates (BIVA:TXG) - TradingView
Price to sales forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
TXG Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x genomics CEO Serge Saxonov sells $1.03m in stock By Investing.com - Investing.com Australia
Form 4 10X Genomics Inc For: 24 June By Investing.com - Investing.com Australia
10x genomics CEO Serge Saxonov sells $1.03m in stock - Investing.com
10x Genomics Insider Sold Shares Worth $1,033,269, According to a Recent SEC Filing - marketscreener.com
10x Genomics (TXG) CEO sells 30,000 shares under 10b5-1 plan - Stock Titan
Why Is 10x Genomics (TXG) Stock Soaring Today - Yahoo Finance
Price to book forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10X Genomics Inc (TXG) Institutional Confidence - TradingKey
10X Genomics stock hits 52-week high at 36.0 USD By Investing.com - Investing.com Australia
10X Genomics stock hits 52-week high at 36.0 USD - Investing.com
10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
10x Genomics boosts single cell proteomics with acquisition of Proteintech Genomics - SelectScience
Insider Sell: Shehnaaz Suliman Sells Shares of 10x Genomics Inc (TXG) - GuruFocus
10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades - Stock Titan
TXG - Finviz
10x Genomics Expands Oncology Diagnostics Ambitions Through Cleveland Clinic Collaboration - BioPharma APAC
10X Genomics stock rises on Cleveland Clinic partnership - Investing.com
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer - BioSpace
10x Genomics (TXG) Partners with Cleveland Clinic for Bladder Ca - GuruFocus
10x Genomics and Cleveland Clinic Collaborate to Advance Researc - GuruFocus
10X Genomics (TXG) Stock Surges 4% Following Cleveland Clinic Bladder Cancer Research Agreement - Blockonomi
10x Genomics, Inc and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer - marketscreener.com
10X Genomics stock rises on Cleveland Clinic partnership By Investing.com - Investing.com India
10x Genomics partners with Cleveland Clinic on bladder cancer study By Investing.com - Investing.com Nigeria
10x Genomics partners with Cleveland Clinic on bladder cancer study - Investing.com
10X Genomics Inc (TXG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
10X Genomics Inc (TXG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
10X Genomics Inc (TXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
10X Genomics Inc (TXG) Valuation: PE, PB & Fair Value Analysis - TradingKey
10X Genomics Inc (TXG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
10x Genomics, Cleveland Clinic study aims to predict bladder cancer treatment response - Stock Titan
10 X Genomics Inc (TXG) 財務データ
収益
当期純利益
現金流量
EPS
10 X Genomics Inc (TXG) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SULIMAN SHEHNAAZ | Director |
Jun 16 '26 |
Sale |
32.63 |
5,723 |
186,756 |
31,722 |
大文字化:
|
ボリューム (24 時間):